Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04788641
Other study ID # D9480C00012
Secondary ID 2020-000515-68
Status Completed
Phase Phase 1
First received
Last updated
Start date March 30, 2021
Est. completion date September 16, 2021

Study information

Verified date April 2024
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will be an open-label, randomised sequence, 2-period, 2-cohort, 2-treatment in each cohort, cross-over study in healthy subjects (males and females of non-childbearing potential), performed at a single study centre.


Description:

The study will comprise: - A screening period of maximum 28 days; - Two treatment periods: - Treatment Period 1 starts with admission to the Clinical Unit on Day -1, followed by dosing on Day 1 with the assigned treatment (A, B, C, or D) as per assigned cohort and treatment sequence, followed by a washout period of at least 14 days. - Treatment Period 2 starts with admission to Clinical Unit on Day -1, followed by dosing on Day 1 with cross-over treatment as per assigned cohort, followed by a follow-up period of 7 to 10 days. - A follow-up visit/early termination visit at 7 to 10 days after the last investigation medicinal product (IMP) administration. Subjects will be assigned to either Cohort 1 (tacrolimus) or to Cohort 2 (cyclosporin). Each cohort will have 2 treatment periods. Subjects in each cohort will be randomly assigned to one of 2 treatment sequences (AB|BA or CD|DC) where, - Treatment A: Tacrolimus - Treatment B: Tacrolimus + SZC - Treatment C: Cyclosporin - Treatment D: Cyclosporin + SZC


Recruitment information / eligibility

Status Completed
Enrollment 62
Est. completion date September 16, 2021
Est. primary completion date September 16, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: • Healthy male and female subjects aged 18 to 50 years (both inclusive) Exclusion Criteria: - History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study. - History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. - Any clinically important abnormalities in rhythm, conduction or morphology of the 12-lead safety electrocardiogram (ECG), at screening visit and/or admission to the Clinical Unit. - Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. - History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to SZC, tacrolimus, or cyclosporin. - Subjects who have previously received SZC.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tacrolimus
Each subject in this cohort will receive a single dose of oral capsules of tacrolimus on 2 occasions, once alone and once in combination with oral suspension of SZC. Drug administrations will occur after a 12 hour overnight fast.
Cyclosporin
Each subject will receive a single dose of oral capsules of cyclosporin on 2 occasions, once alone and once in combination with oral suspension of SZC. Drug administrations will occur after a 12 hour overnight fast.
Sodium Zirconium Cyclosilicate
Each subject will receive single oral doses of SZC with tacrolimus (cohort 1) or cyclosporin (cohort 2) under fasted conditions. The doses will be administered after an overnight fast of at least 12 hours.

Locations

Country Name City State
Germany Research Site Berlin

Sponsors (2)

Lead Sponsor Collaborator
AstraZeneca Parexel

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum Observed Concentration (Cmax) Effect of co-administered SZC on the Cmax of tacrolimus and cyclosporin in healthy participants was determined. Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin
Primary Area Under Concentration-time Curve From Time Zero to Infinity (AUCinf) Effect of co-administered SZC on the AUCinf of tacrolimus and cyclosporin in healthy participants was determined. Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin
Secondary Area Under the Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUClast) Effect of co-administered SZC on the AUClast of tacrolimus and cyclosporin in healthy participants was determined. Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin
Secondary Time to Reach Maximum Observed Concentration Following Drug Administration (Tmax) Effect of co-administered SZC on the tmax of tacrolimus and cyclosporin in healthy participants was determined. Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin
Secondary Half-life Associated With Terminal Slope (?z) of a Semi-logarithmic Concentration-time Curve (t½?z) Effect of co-administered SZC on the t½?z of tacrolimus and cyclosporin in healthy participants was determined. Pre-dose, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, and 72 hours post-dose of tacrolimus or cyclosporin
Secondary Number of Participants With Adverse Events (AEs) and Serious AEs Safety and tolerability of co-administration of SZC and tacrolimus/cyclosporin as compared to tacrolimus/cyclosporin alone was assessed. From the time of IMP administration (Day 1) to Follow-up/Early Termination Visit (7-10 days after last IMP administration) [up to 4 weeks]
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04676646 - Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone Phase 4
Recruiting NCT05347693 - Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Study Phase 4
Completed NCT05271266 - A Multicenter, Prospective, Non-interventional Cohort Study to Evaluate the Safety and Treatment Pattern of Sodium Zirconium Cyclosilicate for Hyperkalaemia Management in Real World Practice in China
Terminated NCT04727528 - Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease Phase 3
Recruiting NCT04249648 - Hyperkalaemia and Its Impact on Therapy With RAASi
Recruiting NCT06185660 - A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greece
Completed NCT05462119 - Safety of Oral Resin for Treatment of Hyperkalemia in Chinese Patients With Renal Insufficiency
Terminated NCT04997161 - Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia Phase 4
Recruiting NCT03813407 - An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia Phase 3

External Links